| Literature DB >> 26900324 |
Debra Akin1, Jeremy R B Newman2, Lauren M McIntyre2, Stephen P Sugrue1.
Abstract
PURPOSE: The specialized corneal epithelium requires differentiated properties, specific for its role at the anterior surface of the eye. Thus, tight maintenance of the differentiated qualities of the corneal epithelial is essential. Pinin (PNN) is an exon junction component (EJC) that has dramatic implications for corneal epithelial cell differentiation and may act as a stabilizer of the corneal epithelial cell phenotype. Our studies revealed that PNN is involved in transcriptional repression complexes and spliceosomal complexes, placing PNN at the fulcrum between chromatin and mRNA splicing. Transcriptome analysis of PNN-knockdown cells revealed clear and reproducible alterations in transcript profiles and splicing patterns of a subset of genes that would significantly impact the epithelial cell phenotype. We further investigated PNN's role in the regulation of gene expression and alternative splicing (AS) in a corneal epithelial context.Entities:
Mesh:
Substances:
Year: 2016 PMID: 26900324 PMCID: PMC4734150
Source DB: PubMed Journal: Mol Vis ISSN: 1090-0535 Impact factor: 2.367
Genes upregulated in response to PNN reduction.
| ALPK2 | 1.12E-41 | 3.85 | alpha-kinase 2 |
| UBC | 7.48E-33 | 2.73 | ubiquitin C |
| MMP13 | 1.69E-28 | 2.63 | matrix metallopeptidase 13 (collagenase 3) |
| TMPRSS11E | 3.82E-28 | 4.26 | transmembrane protease, serine 11E |
| MMP1 | 7.32E-20 | 2.22 | matrix metallopeptidase 1 (interstitial collagenase) |
| BNIP3P4 | 5.40E-14 | 3.54 | BCL2/adenovirus E1B 19 kDa interacting protein 3 pseudogene 4 |
| EGLN1 | 2.93E-13 | 2.83 | egl-9 family hypoxia-inducible factor 1 |
| SLC7A11 | 1.09E-10 | 1.57 | solute carrier family 7 (anionic amino acid transporter light chain, xc- system), member 11 |
| CEACAM6 | 2.38E-10 | 2.12 | carcinoembryonic antigen-related cell adhesion molecule 6 (non-specific cross reacting antigen) |
| CNGB1 | 5.10E-09 | 1.47 | cyclic nucleotide gated channel beta 1 |
| NEFL | 1.38E-08 | 3.12 | neurofilament, light polypeptide |
| MYH15 | 2.83E-08 | 1.76 | myosin, heavy chain 15 |
| PSAT1 | 2.96E-08 | 1.61 | phosphoserine aminotransferase 1 |
| KRT6A | 7.54E-08 | 2.98 | keratin 6A |
| ANKRD22 | 7.54E-08 | 1.70 | ankyrin repeat domain 22 |
| MMP10 | 1.42E-06 | 2.17 | matrix metallopeptidase 10 (stromelysin 2) |
| B3GNT2 | 7.58E-06 | 1.19 | UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2 |
| ADORA2B | 1.82E-05 | 1.22 | adenosine A2b receptor |
| LOC102723439 | 1.86E-05 | 1.62 | uncharacterized LOC102723439 |
| MYO1E | 3.19E-05 | 1.20 | myosin IE |
Genes downregulated in response to PNN reduction.
| ABCA4 | 2.33E-15 | −2.14 | ATP-binding cassette, sub-family A (ABC1), member 4 |
| ABCA4 | 3.78E-14 | −2.46 | ATP-binding cassette, sub-family A (ABC1), member 4 |
| FGD3 | 1.50E-09 | −2.02 | FYVE, RhoGEF and PH domain containing 3 |
| INSL4 | 2.80E-06 | −1.82 | insulin-like 4 (placenta) |
| IGFL1 | 4.07E-06 | −1.68 | IGF-like family member 1 |
| IGFBP5 | 3.46E-05 | −2.05 | insulin-like growth factor binding protein 5 |
| VGLL1 | 3.46E-05 | −1.85 | vestigial-like family member 1 |
| UBD | 3.99E-05 | −1.77 | ubiquitin D |
| CFI | 9.25E-05 | −1.61 | complement factor I |
| PCSK9 | 9.25E-05 | −1.27 | proprotein convertase subtilisin/kexin type 9 |
| SLC1A3 | 0.00024818 | −1.04 | solute carrier family 1 (glial high affinity glutamate transporter), member 3 |
| DHRS3 | 0.00057796 | −1.28 | dehydrogenase/reductase (SDR family) member 3 |
| VGLL1 | 0.00132719 | −1.65 | vestigial-like family member 1 |
| CDH5 | 0.00132719 | −1.49 | cadherin 5, type 2 (vascular endothelium) |
| RPS24 | 0.00133766 | −0.99 | ribosomal protein S24 |
| LINC01559 | 0.00180566 | −1.05 | long intergenic non-protein coding RNA 1559 |
| RPS24 | 0.00238888 | −0.94 | ribosomal protein S24 |
| CLEC7A | 0.00263968 | −1.49 | C-type lectin domain family 7, member A |
| RARRES3 | 0.00294625 | −1.07 | retinoic acid receptor responder (tazarotene induced) 3 |
Gene Ontology of genes upregulated in response to PNN reduction.
| GO:0030334 | regulation of cell migration | 3.28E-08 | 3.79E-04 | 3.73 | MMP10, EGFR, CXCL3, MMP9, STC1, CXCL1, UNC5C, HAS2, CXCL2, TRIB1, STRAP, LAMA3 |
| GO:0006520 | cellular amino acid metabolic process | 9.41E-08 | 5.44E-04 | 4.8 | EGLN1, PSAT1, PLA2G4E, GARS, MTHFD2L, GLS |
| GO:0030198 | extracellular matrix organization | 1.03E-07 | 3.98E-04 | 5.09 | MMP13, MMP1, MMP10, MYO1E, ANXA2, MMP9, SERPINb5, CD44, LAMC!, HAS2, LAMC2, LAM3 |
| GO:0043062 | extracellular structure organization | 1.03E-07 | 2.98E-04 | 5.09 | MMP1, TIMP1, ACTN1. LAMC2, MMP13, TNC, SERPINB5, CD47, CD44, MMP9, ITGA2, SDC4 |
| GO:0044822 | poly(A) RNA binding | 2.03E-09 | 6.63E-06 | 1.63 | UBC, ANXA2, NQo1, NAA38, RPS16, RRP12, STRAP |
| GO:0045236 | CXCR chemokine receptor binding | 2.18E-08 | 2.37E-05 | 64.04 | CXCL3, CXCL1, CXCL2, YARS |
| GO:0004222 | metalloendopeptidase activity | 1.27E-06 | 1.03E-03 | 25.32 | MMP10, ADAMS6, ADAM19, MMP13, MMP1, MMP9 |
Gene Ontology of genes downregulated in response to PNN reduction.
| GO:0044283 | small molecule biosynthetic process | 3.65E-06 | 4.26E-03 | 2.41 | SLC1A3, MNGCR, EBP, DHCR7,CYP51A1, FADS2, PADI2, HMGSC1 |
| GO:1901624 | negative regulation of lymphocyte chemotaxis | 9.55E-06 | 9.28E-03 | 57.75 | KLRK1, CCL2, PADI2 |
| GO:0002376 | immune system process | 3.52E-05 | 2.28E-02 | 1.37 | UBD, CFI, RPS24, CLEC7A, IFITM2, ADCY5, IL7R, KITLG |
| GO:2000402 | negative regulation of lymphocyte migration | 5.61E-05 | 3.27E-02 | 43.31 | CCL2, PADI2, KLRK1 |
| GO:0045595 | regulation of cell differentiation | 5.94E-05 | 3.30E-02 | 1.41 | IGFBP5, IL7R, KITLG |
| GO:0050793 | regulation of developmental process | 9.10E-05 | 4.82E-02 | 1.33 | FGD3, IGFB5, COLQ, HMGCR, |
| GO:0032808 | lacrimal gland development | 9.85E-05 | 5.00E-02 | 16.49 | RARG, FGFR2, PAX6, SOX10 |
Figure 1Gene Ontology of genes upregulated in response to PNN knockdown and graphical output of GOrilla for the ranked list of genes upregulated after PNN knockdown. This Gene Ontology (GO) graph generated by GOrilla for identifying and visualizing enriched GO terms in ranked lists of upregulated GOrilla searches for enriched GO terms that appear densely at the top of a ranked list of genes. The system used 13,033 genes that are associated with a GO term GO database and other sources. This figure represents a small portion of the output depicting the pathways associated with enhanced cell migration. The genes identified in this cell behavior are presented in Table 3.
Verification of expression changes by droplet digital pcr quantitation.
| Variables | PNN | MMP1 | MMP9 | MMP13 | VEGFa |
|---|---|---|---|---|---|
| Control* | 0.061 | 0.0098 | 0.0025 | 0.0068 | 0.0111 |
| PNN knock down* | 0.016 | 0.0316 | 0.0043 | 0.0272 | 0.0156 |
| P value | 0.0001 | 0.0014 | 0.0093 | 0.0008 | 0.0012 |
| log2 Fold change | -1.93 | 1.69 | 0.78 | 2 | 0.49 |
*Data presented as relative to GAPDH
Figure 2MMP9 protein upregulated after PNN knockdown in HCET cells. Immunofluorescence micrographs depicted the upregulation of the MMP9 protein in human corneal epithelial (HCET) cells after pinin (PNN) knockdown.
Figure 3Widespread changes in splicing events after PNN knockdown. A scatterplot of splicing events detected in pinin (PNN) knockdown and control cells (the overlapping area in the Venn diagrams), plotting the mean expression (as log2 APN) of the control cells versus the PNN-knockdown cells. Differentially expressed events are red (upregulated) and blue (downregulated), and non-differentially expressed events are in black. More than 70% of significantly different events are upregulated in PNN (p<0.0001). All types of events are biased toward upregulation in PNN (92.5% of all events, 91.8% of exon-skipping events (635 of 692 differentially expressed [DE] events), 94.1% of alternative donor sites (531 of 564 DE events), 93.0% of alternative receptor sites (490 of 527 DE events), 93.7% of events involving alternative donors and acceptors (554 of 591 DE events), and 62.9% of intron retention events (95 of 151 DE events).
RNA Splicing events.
| RAD54L2andTEX264 | EJ | E-E j. between exon(s) 22 and exons(s) 23 of RAD54L2andTEX264 | 0.0001 | 1.28 |
| KIAA0368andOR2K2 | EJ | E-E j. between exon(s) 11|13 and exons(s) 14|15 of KIAA0368andOR2K2 | 0.0001 | 1.31 |
| BUB1 | EJ | E-E j. between exon(s) 28|29 and exons(s) 30 of BUB1 | 0.0001 | 1.66 |
| ITGA6 | EJ | E-E j. between exon(s) 7|8 and exons(s) 9 of ITGA6 | 0.0001 | 1.73 |
| MARK3 | EJ: AD, AA | E-E j. between exon(s) 26 and exons(s) 29 of MARK3 | 0.0001 | 1.74 |
| ERO1L | EJ | E-E j. between exon(s) 11|12 and exons(s) 13 of ERO1L | 0.0001 | 1.76 |
| NPAS2 | EJ: AD | E-E j. between exon(s) 6|8|9 and exons(s) 10 of NPAS2 | 0.0001 | 1.95 |
| MALT1 | EJ | E-E j. between exon(s) 9 and exons(s) 10 of MALT1 | 0.0001 | 2.23 |
| NEDD9 | EJ | E-E j. between exon(s) 6 and exons(s) 7|8 of NEDD9 | 0.0002 | 0.27 |
| FAM73A | EJ | E-E j. between exon(s) 12 and exons(s) 13 of FAM73A | 0.0002 | 1.30 |
| PRKDC | EJ: AD | E-E j. between exon(s) 96 and exons(s) 98 of PRKDC | 0.0002 | 1.36 |
| RDX | EJ | E-E j. between exon(s) 22 and exons(s) 23 of RDX | 0.0002 | 1.52 |
| IFT140 | EJ | E-E j. between exon(s) 31 and exons(s) 32 of IFT140 | 0.0002 | 1.55 |
| RDX | EJ: ES [ | E-E j. between exon(s) 18 and exons(s) 21 of RDX, skipping 1 exon | 0.0002 | 1.60 |
| LAMC1 | EJ | E-E j. between exon(s) 33|34 and exons(s) 35 of LAMC1 | 0.0002 | 1.60 |
| MYO1E | EJ | E-E j. between exon(s) 19 and exons(s) 20 of MYO1E | 0.0002 | 1.64 |
| RPS5 | EJ: ES [ | E-E j. between exon(s) 7|9 and exons(s) 12|13|14 of RPS5, skipping 1 exon | 0.0002 | 1.70 |
| SNRNP200 | EJ | E-E j. between exon(s) 52 and exons(s) 53 of SNRNP200 | 0.0002 | 1.80 |
| EPRS | EJ | E-E j. between exon(s) 27 and exons(s) 28 of EPRS | 0.0002 | 1.90 |
| KIAA1632 | EJ | E-E j. between exon(s) 13 and exons(s) 14 of KIAA1632 | 0.0002 | 1.94 |
(E-E j.=exon-exon junction, EJ=exon junction, ES=exon-skipping, AD=alternative donor, AA=alternative acceptor, IR=intron retention)
Splicing events correlated to change in transcripts known splice isoforms.
| NF2 | 0.0129 | NF2, transcript variant 5 | 3.87 | NF2, transcript variant 8 | −0.71 |
| PCNX | 0.0099 | PCNX, transcript variant X10 | 3.59 | PCNX, transcript variant X2 | −1.67 |
| SRPK2 | 0.043 | SRPK2, transcript variant 2 | 3.32 | SRPK2, transcript variant X3 | −2.68 |
| FAM73A | 0.0139 | FAM73A, transcript variant 1 | 3.09 | FAM73A, transcript variant X3 | −2.86 |
| MTHFD2L | 0.0179 | MTHFD2L, transcript variant X2 | 2.73 | MTHFD2L, transcript variant X1 | −0.38 |
| ABHD2 | 0.0242 | ABHD2, transcript variant X1 | 2.51 | ABHD2, transcript variant X2 | −1.34 |
| C1orf27 | 0.0196 | C1orf27, transcript variant 3 | 2.17 | C1orf27, transcript variant X4 | −1.29 |
| NAE1 | 0.0055 | NAE1, transcript variant X2 | 1.93 | NAE1, transcript variant 2 | −0.99 |
| SMEK2 | 0.0288 | SMEK2, transcript variant X6 | 1.80 | SMEK2, transcript variant X7 | −0.09 |
| FBXO38 | 0.0356 | FBXO38, transcript variant 3 | 1.75 | FBXO38, transcript variant X3 | −1.17 |
| FKBP14 | 0.0362 | FKBP14, transcript variant 2, non-coding RNA | 1.74 | FKBP14, RefSeqGene (LRG_454) on chromosome 7 | −0.02 |
| GTF2H1 | 0.0475 | GTF2H1, transcript variant 2 | 1.64 | GTF2H1, transcript variant X1 | −0.50 |
| HUWE1 | 0.0004 | HUWE1, transcript variant X5 | 1.59 | HUWE1, transcript variant X2 | −0.28 |
| SLC38A9 | 0.0457 | SLC38A9, transcript variant X2 | 1.59 | SLC38A9, transcript variant X8, misc_RNA | −0.62 |
| SLC7A11 | 0.0174 | SLC7A11 | 1.57 | SLC7A11 transcript variant X1 | −0.04 |
| SRGAP2 | 0.0091 | SRGAP2, transcript variant X7 | 1.47 | SRGAP2, RefSeqGene on chromosome 1 | −0.22 |
| ADAM19 | 0.0346 | ADAM19 | 1.47 | ADAM19, transcript variant X1 | −0.23 |
| FANCL | 0.0354 | FANCL, transcript variant X5, misc_RNA | 1.42 | LRG_501 on chromosome 2 | −0.35 |
| FOSL1 | 0.0433 | FOSL1, transcript variant 1 | 1.40 | FOSL1, transcript variant 5 | −1.39 |
Splicing events correlated to upregulated genes.
| MMP13 | 0.0003 | matrix metallopeptidase 13 (collagenase 3; MMP13) | 1.08E-32 | 2.63 |
| MMP1 | 0.0002 | matrix metallopeptidase 1 (interstitial collagenase; MMP1), transcript variant 1 | 7.83E-24 | 2.22 |
| MYH15 | 0.0214 | myosin, heavy chain 15 (MYH15) | 1.03E-11 | 1.76 |
| PSAT1 | 0.0009 | phosphoserine aminotransferase 1 (PSAT1), transcript variant 1 | 1.14E-11 | 1.61 |
| ANKRD22 | 0.0035 | ankyrin repeat domain 22 (ANKRD22) | 3.11E-11 | 1.70 |
| MYO1E | 0.0001 | myosin IE (MYO1E) | 1.84E-08 | 1.20 |
| ADAMTS6 | 0.0067 | ADAM metallopeptidase with thrombospondin type 1 motif, 6 (ADAMTS6) | 3.67E-08 | 1.12 |
| FERMT1 | 0.0089 | fermitin family member 1 (FERMT1) | 3.93E-08 | 1.39 |
| EGFR | 0.0005 | epidermal growth factor receptor (EGFR), transcript variant 1 | 5.97E-08 | 1.49 |
| EFNB2 | 0.002 | ephrin-B2 (EFNB2) | 0.000000136 | 1.06 |
| AGPAT9 | 0.0115 | 1-acylglycerol-3-phosphate O-acyltransferase 9 (AGPAT9), transcript variant 1 | 0.000000144 | 3.05 |
| SLC20A1 | 0.0034 | solute carrier family 20 (phosphate transporter), member 1 (SLC20A1) | 0.000000388 | 1.44 |
| STC2 | 0.0131 | stanniocalcin 2 (STC2) | 0.000000727 | 1.00 |
| XPOT | 0.003 | exportin, tRNA (XPOT) | 0.00000128 | 0.98 |
| GARS | 0.0083 | glycyl-tRNA synthetase (GARS), transcript variant X1 | 0.00000147 | 0.97 |
| STC1 | 0.0032 | stanniocalcin 1 (STC1) | 0.00000168 | 1.11 |
| NQO1 | 0.0055 | NAD(P)H dehydrogenase, quinone 1 (NQO1), transcript variant 1 | 0.00000456 | 1.33 |
| CD55 | 0.0039 | CD55 molecule, decay accelerating factor for complement (Cromer blood group; CD55), transcript variant 1 | 0.00000608 | 1.08 |
| SERPINB5 | 0.0015 | serpin peptidase inhibitor, clade B (ovalbumin), member 5 (SERPINB5) | 0.00000683 | 0.90 |
| TMTC2 | 0.0446 | transmembrane and tetratricopeptide repeat containing 2 (TMTC2), transcript variant X1 | 0.00000708 | 1.68 |
| CD44 | 0.041 | CD44 molecule (Indian blood group; CD44), RefSeqGene on chromosome 11 | 0.000014 | 0.87 |
Splicing events correlated to downregulated genes.
| FGD3 | 0.0044 | FYVE, RhoGEF and PH domain containing 3 (FGD3), transcript variant X2, misc_RNA | 4.16E-13 | −2.02 |
| CDH5 | 0.0141 | cadherin 5, type 2 (vascular endothelium; CDH5), mRNA | 0.00000179 | −1.49 |
| CASP1 | 0.0096 | caspase 1, apoptosis-related cysteine peptidase (CASP1), RefSeqGene on chromosome 11 | 0.003233781 | −0.85 |
| C3 | 0.0033 | complement component 3 (C3), mRNA | 0.004117402 | −0.57 |
| RDH10 | 0.0204 | retinol dehydrogenase 10 (all-trans; RDH10), mRNA | 0.009398676 | −0.70 |
| NEO1 | 0.041 | neogenin 1 (NEO1), RefSeqGene on chromosome 15 | 0.00995951 | −0.55 |
| CDH11 | 0.0139 | cadherin 11, type 2, OB-cadherin (osteoblast; CDH11), RefSeqGene on chromosome 16 | 0.01161935 | −0.52 |
| PCTP | 0.0151 | phosphatidylcholine transfer protein (PCTP), transcript variant X4, misc_RNA | 0.014216733 | −1.20 |
| SP110 | 0.0143 | SP110 nuclear body protein (SP110), RefSeqGene (LRG_109) on chromosome 2 | 0.015998943 | −0.50 |
| NIPSNAP1 | 0.0173 | nipsnap homolog 1 (C. elegans; NIPSNAP1), transcript variant X1, mRNA | 0.016613623 | −0.47 |
| BCAS1 | 0.0022 | breast carcinoma amplified sequence 1 (BCAS1), transcript variant X9, mRNA | 0.025350687 | −4.06 |
| GABRP | 0.0273 | gamma-aminobutyric acid (GABA) A receptor, pi (GABRP), transcript variant 2, mRNA | 0.031249095 | −2.79 |
| SYCE1L | 0.0262 | synaptonemal complex central element protein 1-like (SYCE1L), mRNA | 0.032750969 | −0.98 |
| PROM1 | 0.0258 | prominin 1 (PROM1), RefSeqGene on chromosome 4 | 0.038456406 | −0.54 |
| BRAF | 0.029 | B-Raf proto-oncogene, serine/threonine kinase (BRAF), RefSeqGene (LRG_299) on chromosome 7 | 0.042463081 | −0.53 |
| SIAE | 0.0287 | sialic acid acetylesterase (SIAE), RefSeqGene on chromosome 11 | 0.047026974 | −0.54 |
| VIPR1 | 0.0068 | vasoactive intestinal peptide receptor 1 (VIPR1), RefSeqGene on chromosome 3 | 0.047041988 | −0.49 |
| BAZ2B | 0.0057 | bromodomain adjacent to zinc finger domain, 2B (BAZ2B), transcript variant 3, non-coding RNA | 0.047636931 | −0.73 |